Immuta stock $5.72 USD
Private-market facts for current and former Immuta employees researching their stock.
Price per share sourced from public secondary-market data. Updated April 2026. Indicative only — not a live quote.
Overview
Data security platform providing automated access control, privacy protection, and governance for cloud data platforms.
Selling Immuta shares
Why shareholders consider selling
Shareholders in Immuta may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Immuta does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Immuta stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Data & Analytics sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Immuta shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Immuta shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Data & Analytics market conditions, and any recent private-market transaction activity. Data points such as the company's Series D round, its reported $1B valuation and recent secondary-market pricing can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Immuta shareholders
Exploring equity in Immuta often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Immuta most recently raised a Series D round in May 2022. The company was valued at $1B. Total funding raised to date is approximately $267M.
Lead investors in this round include NightDragon and Intel Capital.
Founders & company background
Immuta was founded in 2015 by Matthew Carroll, Steve Touw and is headquartered in College Park, MD.
Investors
Industry
Similar private companies
Latest Immuta news
Frequently asked questions
- Is Immuta still a private company?
- Yes, Immuta is currently a private company.
- What is Immuta's latest funding round?
- Immuta's most recent known round is Series D, raised in May 2022.
- What is Immuta's valuation?
- Immuta's latest reported valuation is $1B.
- Who are the investors in Immuta?
- Notable investors include NightDragon, Intel Capital, DFJ Growth, March Capital Partners.
- Can I sell my Immuta stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Immuta stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Immuta data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.